Skip to main content


The power of gene therapy can change more than words.
It can transform the future.

At Passage Bio, our mission is to improve the lives of patients with neurodegenerative diseases by delivering genetic medicines that will permanently redefine the course of their conditions.

Advancing Lead Clinical Programs in Neurodegenerative Diseases

upliFT-D Logo

Our Phase 1/2 Study in Frontotemporal Dementia (FTD)

The upliFT-D study is a multinational Phase 1/2 clinical trial evaluating the safety and efficacy of PBFT02, a novel and potentially transformative gene therapy for patients with FTD with progranulin gene mutations.

Read the latest news about Passage Bio

Improving the Lives of People Affected by CNS Diseases

People living or born with CNS diseases are at the center of every decision we make. We strive to turn disbelief into belief, disease into ease, and the incurable into the curable. That’s what it means to protect patients and their families against loss in neurodegenerative diseases.